Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MiCardia CE marks enCor heart valve repair device

This article was originally published in Clinica

Executive Summary

MiCardia’s enCor mitral valve repair system is now available in Europe after the firm CE marked it. It is intended for patients with mitral valve regurgitation, where the mitral valve in the heart does not close tightly, allowing blood to flow backwards. The device, an annulosplasty ring, can be adjusted during surgery to correct any residual mitral valve regurgitation in real time on a beating heart. Irvine, California-based MiCardia is also developing a next-generation device, enCorSQ, which clinicians can adjust during minimally invasive surgery. It is designed to treat recurrent regurgitation weeks, months or years after the initial surgery. Around 20,000 mitral valve repair procedures are performed in Europe each year, MiCardia estimates.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel